Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Animal Origin Free STEMzyme™ Collangenase/Neutral Protease Blends

Published: Tuesday, May 14, 2013
Last Updated: Monday, May 13, 2013
Bookmark and Share
Designed for stem cell isolation, regenerative medicine & bioprocessing applications.

Worthington's new Animal Origin Free (AOF) STEMzyme™ Collagenase/Neutral Protease (Dispase®) Blends 1 and 2 are now available for primary and stem cell isolation, regenerative medicine, biopharma & cell bioprocessing applications.

STEMzyme™ 1 & 2 Collagenase/Neutral Protease (Dispase®) are specialized combinations of AOF Clostridium histolyticum Collagenase (Code: CLSAFB) and AOF Bacillus polymyxa Neutral Protease (Dispase®) with a minimum of 250 CLS units and 1,000 or 2,000 caseinase units per mg dry weight, respectively.

Produced at Worthington and designed for stem cell, regenerative medicine and other primary cell isolations and bioprocessing applications where introduction of potential animal derived pathogens must be prevented.

As an ISO9001 Certified primary manufacturer, Worthington can meet enzyme requirements from research-scale to bulk bioprocessing quantities.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
More Effective Strategy for Producing Flu Vaccines
Researchers have developed a virus backbone, allowing producers to grow vaccine viruses in mammalian cells, rather than in eggs.
Improving Drug Production with Computer Model
A model has been developed that can be used to improve and accelerate the production of biotherapeutics, cancer drugs, and vaccines.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!